Published in Br J Cancer on March 27, 2006
Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev (2013) 1.14
Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS One (2011) 1.06
Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering. Nat Chem (2014) 1.05
Remotely triggered cisplatin release from carbon nanocapsules by radiofrequency fields. Biomaterials (2012) 0.97
beta-Secretase inhibitor potency is decreased by aberrant beta-cleavage location of the "Swedish mutant" amyloid precursor protein. J Biol Chem (2009) 0.96
The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol (2010) 0.96
Acidic extracellular pH neutralizes the autophagy-inhibiting activity of chloroquine: implications for cancer therapies. Autophagy (2014) 0.94
The tumor microenvironment and strategies to improve drug distribution. Front Oncol (2013) 0.93
Importance of intracellular pH in determining the uptake and efficacy of the weakly basic chemotherapeutic drug, doxorubicin. PLoS One (2012) 0.85
Chloroquine-enhanced efficacy of cisplatin in the treatment of hypopharyngeal carcinoma in xenograft mice. PLoS One (2015) 0.85
Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy. Br J Cancer (2015) 0.82
Development of drug loaded nanoparticles for tumor targeting. Part 1: Synthesis, characterization, and biological evaluation in 2D cell cultures. Nanoscale (2013) 0.81
Reversion of pH-induced physiological drug resistance: a novel function of copolymeric nanoparticles. PLoS One (2011) 0.81
A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin. Invest New Drugs (2014) 0.80
Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors. Cancer Sci (2015) 0.78
Lysosomal drug sequestration as a mechanism of drug resistance in vascular sarcoma cells marked by high CSF-1R expression. Vasc Cell (2014) 0.78
Intracellular trafficking as a determinant of AS-DACA cytotoxicity in rhabdomyosarcoma cells. BMC Cell Biol (2011) 0.76
Chloroquine enhances the efficacy of cisplatin by suppressing autophagy in human adrenocortical carcinoma treatment. Drug Des Devel Ther (2016) 0.76
Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells. Oncogene (2016) 0.76
The (pro)renin receptor mediates constitutive PLZF-independent pro-proliferative effects which are inhibited by bafilomycin but not genistein. Int J Mol Med (2014) 0.75
Polymeric chloroquine as an inhibitor of cancer cell migration and experimental lung metastasis. J Control Release (2016) 0.75
Sequestration of AS-DACA into acidic compartments of the membrane trafficking system as a mechanism of drug resistance in rhabdomyosarcoma. Int J Mol Sci (2013) 0.75
The distribution and retention of paclitaxel and doxorubicin in multicellular layer cultures. Oncol Rep (2012) 0.75
Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action? Eur J Clin Microbiol Infect Dis (2014) 0.75
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer. Int J Mol Sci (2017) 0.75
Low concentration of chloroquine enhanced efficacy of cisplatin in the treatment of human ovarian cancer dependent on autophagy. Am J Transl Res (2017) 0.75
Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J Cell Biol (1981) 6.63
Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev (1990) 2.75
Doxorubicin gradients in human breast cancer. Clin Cancer Res (1999) 2.36
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res (2005) 2.33
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res (2002) 2.05
Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med (1998) 1.89
Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine. Biochem Biophys Res Commun (1988) 1.88
Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell (2003) 1.77
Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer (1998) 1.61
Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta (1986) 1.52
Distribution and activity of antineoplastic drugs in a tumor model. J Natl Cancer Inst (1989) 1.49
Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists. N Engl J Med (1984) 1.36
Defective pH regulation of acidic compartments in human breast cancer cells (MCF-7) is normalized in adriamycin-resistant cells (MCF-7adr). Biochemistry (1996) 1.26
Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res (1999) 1.24
Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta (1991) 1.20
Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Biochem Pharmacol (1996) 1.08
Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes. Blood (1997) 1.07
An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br J Cancer (1997) 0.98
Role of organelle pH in tumor cell biology and drug resistance. Drug Discov Today (1999) 0.96
The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers. Int J Cancer (2000) 0.93
Pharmacokinetic aspects of chloroquine-induced pruritus: influence of dose and evidence for varied extent of metabolism of the drug. Eur J Pharm Sci (2001) 0.92
Multilayers of cells growing on a permeable support. An in vitro tumour model. Acta Oncol (1997) 0.90
Mechanistic studies of enhanced in vitro radiosensitization and hypoxic cell cytotoxicity by targeting radiosensitizers to DNA via intercalation. Int J Radiat Oncol Biol Phys (1992) 0.86
Factors that influence the penetration of methotrexate through solid tissue. Int J Cancer (2001) 0.86
Correlation between drug uptake and selective toxicity of porfiromycin to hypoxic EMT6 cells. Cancer Res (1987) 0.82
Anti-malarial chloroquine stimulate p53-apoptotic pathway in rat hepatocytes. J Egypt Soc Parasitol (2005) 0.80
The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer (1968) 4.88
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol (2013) 2.51
Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res (1970) 2.47
Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol (2000) 2.34
Unconventional therapies for cancer: a refuge from the rules of evidence? CMAJ (1998) 2.24
Perception of quality of life by patients, partners and treating physicians. Qual Life Res (2000) 2.04
Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol (1999) 2.03
Quality of cancer care. Ann Oncol (2004) 2.01
Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol (2007) 1.88
The proliferation of capillary endothelial cells. Cancer Res (1972) 1.81
Bone metastases: pathophysiology and management policy. J Clin Oncol (1991) 1.70
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. Br J Cancer (1980) 1.68
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol (2008) 1.67
Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. Br J Radiol (1972) 1.67
How expert physicians would wish to be treated if they had genitourinary cancer. J Clin Oncol (1988) 1.65
Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol (2001) 1.57
Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer (2006) 1.54
The fate of abstracts submitted to a cancer meeting: factors which influence presentation and subsequent publication. Ann Oncol (1992) 1.54
Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer (2001) 1.47
Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol (2007) 1.42
Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol (2006) 1.39
Quantitative techniques for study of the anatomy and function of small blood vessels in tumors. J Natl Cancer Inst (1969) 1.39
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol (2003) 1.35
In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: methotrexate, 5-fluorouracil and adriamycin. Br J Cancer (1980) 1.33
Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1996) 1.32
Influence of vitamin A on immunological response. Immunology (1972) 1.28
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol (1997) 1.25
Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin Cancer Res (1999) 1.24
Measuring health-related quality of life in clinical trials that evaluate the role of chemotherapy in cancer treatment. CMAJ (1998) 1.20
Influence of hypoxia and an acidic environment on the metabolism and viability of cultured cells: potential implications for cell death in tumors. Cancer Res (1986) 1.19
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol (1998) 1.17
On the existence of a G 0 -phase in the cell cycle. Cell Tissue Kinet (1970) 1.17
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol (2014) 1.17
High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol (1998) 1.12
Reduction of intracellular pH as a possible mechanism for killing cells in acidic regions of solid tumors: effects of carbonylcyanide-3-chlorophenylhydrazone. Cancer Res (1989) 1.10
The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase. Br J Cancer (1998) 1.09
Vitamin A and the radiation response of experimental tumors: an immune-mediated effect. J Natl Cancer Inst (1972) 1.09
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol (1994) 1.07
Therapeutic potential of analogues of amiloride: inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy. Br J Cancer (1993) 1.07
Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol (2013) 1.06
Activity of mitomycin C for aerobic and hypoxic cells in vitro and in vivo. Cancer Res (1983) 1.05
The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects. Br J Cancer (1996) 1.05
Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions. Cancer Res (1992) 1.04
Effect of transient hypoxia on sensitivity to doxorubicin in human and murine cell lines. J Natl Cancer Inst (1990) 1.04
Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1999) 1.03
Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res (1998) 1.02
A comparison of cell proliferation parameters in solid and ascites Ehrlich tumors. Cancer Res (1969) 1.00
Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer. J Clin Oncol (1986) 0.99
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br J Cancer (1997) 0.98
Tumor growth and cell kinetics in chronically hypoxic animals. J Natl Cancer Inst (1970) 0.97
Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment. Br J Cancer (1993) 0.96
Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol (1985) 0.94
Systemic treatment for prostate cancer. Cancer Treat Rev (1998) 0.94
Experimental chemotherapy and concepts related to the cell cycle. Int J Radiat Biol Relat Stud Phys Chem Med (1986) 0.94
Influence of glucose concentration on growth and formation of necrosis in spheroids derived from a human bladder cancer cell line. Cancer Res (1986) 0.94
Chemotherapy for adenocystic carcinoma. Cancer (1980) 0.93
How valid are claims for synergy in published clinical studies? Ann Oncol (2012) 0.93
Prostate cancer: 11. Alternative approaches and the future of treatment. CMAJ (1999) 0.93
Cytostatic potential of novel agents that inhibit the regulation of intracellular pH. Br J Cancer (2002) 0.93
The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers. Int J Cancer (2000) 0.93
Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study. Ann Oncol (2009) 0.92
A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. Oral Oncol (2002) 0.90
Flow cytometric analysis of doxorubicin accumulation in cells from human and rodent cell lines. J Natl Cancer Inst (1989) 0.90
The translational research chain: is it delivering the goods? Int J Radiat Oncol Biol Phys (2001) 0.90
Treating the patient, not just the cancer. N Engl J Med (1987) 0.89
Removing the primary tumor after the cancer has spread. N Engl J Med (2001) 0.89
Is there a role for chemotherapy in prostate cancer? Br J Cancer (2004) 0.89
Quality of life and understanding of disease status among cancer patients of different ethnic origin. Br J Cancer (2003) 0.88
Global drug development in cancer: a cross-sectional study of clinical trial registries. Ann Oncol (2009) 0.88
Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. Ann Oncol (2009) 0.88
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol (1998) 0.87
Lysosomes, lysosomal enzymes, and cancer. Adv Cancer Res (1993) 0.87
Factors that influence the penetration of methotrexate through solid tissue. Int J Cancer (2001) 0.86
Reduction of tumour intracellular pH and enhancement of melphalan cytotoxicity by the ionophore Nigericin. Int J Cancer (1995) 0.86
Variation of pO2 in the growth medium of spheroids: interaction with glucose to influence spheroid growth and necrosis. Br J Cancer (1986) 0.86
The changing face of hormonal therapy for prostate cancer. Ann Oncol (2008) 0.85
Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer. J Clin Oncol (1999) 0.85
Comparison of growth of human bladder cancer in tissue culture or as xenografts with clinical and pathological characteristics. Cancer Res (1984) 0.85
Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience. Br J Urol (1998) 0.84
Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy. Br J Cancer (1994) 0.84
The potential of lactate and succinate to kill nutrient deprived tumor cells by intracellular acidification. Int J Radiat Oncol Biol Phys (1991) 0.84
Quality of life measurement in breast cancer patients. Br J Cancer (1985) 0.84
Chemotherapy for patients with hormone-refractory prostate cancer. Ann Oncol (2004) 0.83
Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues? Br J Cancer (1990) 0.83
Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study. Cytometry A (2003) 0.82
Responsibility in advertising: an oncologist's view. N Engl J Med (1979) 0.82
Chemotherapy for head and neck cancer. J Otolaryngol (1984) 0.82
Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J Clin Oncol (1999) 0.82
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis (2008) 0.82
Influence of cell concentration in limiting the therapeutic benefit of P-glycoprotein reversal agents. Int J Cancer (1999) 0.81
The recruitment of patients into clinical trials. Br J Cancer (1995) 0.81
Antitumor activity of nigericin and 5-(N-ethyl-N-isopropyl)amiloride: an approach to therapy based on cellular acidification and the inhibition of regulation of intracellular pH. Oncol Res (1994) 0.81
Malignant properties of sublines selected from a human bladder cancer cell line that contains an activated c-Ha-ras oncogene. Cancer Res (1988) 0.80
A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat (2012) 0.80